Therapeutic methods for inhibiting tumor growth with...

Details Therapeutic methods for inhibiting tumor growth with... Therapeutic methods for inhibiting tumor growth with...

2009-05-04

2011-11-01

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S174100, C514S008100, C514S019300, C530S387300

Reexamination Certificate

active

08048418

ABSTRACT:
Disclosed is a therapeutic method for inhibiting development or growth of tumors that are resistant to the blockade of delta-like ligand 4 (Dll4), or vascular endothelial growth factor (VEGF), or to other therapeutic agents, by administering the combination of Dll4 antagonist and VEGF antagonist. The combined administration of these two agents, concurrently or sequentially, exhibits synergistic effects on blood vessel development and growth, thereby more effectively inhibiting the tumor growth than an administration of either agent alone. The Dll4 antagonist can be an anti-Dll4 antibody or antibody fragment capable of inhibiting the binding of Dll4 to a Notch receptor, or a fusion protein comprising the extracellular domain of Dll4 or a soluble Notch receptor, or a fragment thereof, fused to a multimerizing component. The VEGF antagonist can be a VEGF trap, anti-VEGF antibody or antibody fragment capable of inhibiting the binding of VEGF to a VEGF receptor.

REFERENCES:
patent: 6121045 (2000-09-01), McCarthy et al.
patent: 6379925 (2002-04-01), Kitajewski et al.
patent: 6664098 (2003-12-01), Sakano
patent: 6984522 (2006-01-01), Clark et al.
patent: 7022499 (2006-04-01), Sakano
patent: 7087411 (2006-08-01), Daly et al.
patent: 2006/0030694 (2006-02-01), Kitajewski et al.
patent: 2006/0122373 (2006-06-01), McCarthy et al.
patent: 2007/0213266 (2007-09-01), Gill et al.
patent: 2008/0014196 (2008-01-01), Yan
patent: 2008/0175847 (2008-07-01), Yan et al.
patent: 1004669 (2000-05-01), None
patent: WO98/45434 (1998-10-01), None
patent: WO03/042246 (2003-05-01), None
patent: WO03/050502 (2003-06-01), None
Duarte, A., et al. (2004) Dosage-sensitive requirement for mouse Dll4 in artery development. Gene & Dev. 18: doi: 10.1101/gad.1239004.
Gale, N.W. et al. (2004) Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl. Acad. Sci. USA. 101(45):15949-15954.
Krebs, L.T., et al. (2004) Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Gene & Dev. 18: doi: 10.1101/gad.1239204.
Liu, Z-J., et al. (2003) Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis. Mo. Cell. Bio. 23(1):14-25.
Mailhos, C., et al. (2001) Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation. 69(2-3):135-144.
Noguera I. et al. (2005) Expression of Delta-like 4 (Dll4) ligand in mouse tumor models. Proceedings of the Annual Meeting of the American Association for Cancer Research 46(Suppl S):1104.
Patel, N.S. et al. (2005) Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function. Cancer Research 65(19):8690-8697.
Shutter, J.R., et al. (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Gene & Dev. 14:1313-1318.

Affiliated with

Also associated with

Rating

Therapeutic methods for inhibiting tumor growth with... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic methods for inhibiting tumor growth with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods for inhibiting tumor growth with... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4297647